Objective-To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels. Methods and Results-New Zealand white rabbits received normal chow or chow supplemented with 0.6% or 1.2%
N iacin (nicotinic acid) has been used for more than 30 years to treat plasma lipid disorders and to prevent atherosclerotic cardiovascular disease. 1 At pharmacological doses, niacin reduces low-density lipoprotein cholesterol, plasma triglyceride, nonesterified fatty acid, and lipoprotein(a) levels. Niacin also increases the concentration of high-density lipoproteins (HDLs). 2 Human intervention studies have indicated that treatment with niacin, either alone or in combination with other lipid-lowering agents, can slow or reverse the progression of atherosclerosis and reduce cardiovascular event rates and total mortality in patients with hypercholesterolemia and established atherosclerotic cardiovascular disease. 2 In combination therapy with statins, niacin reduces cardiovascular events 3 and slows coronary atherosclerosis progression. 4 It also reduces coronary stenosis progression in patients with metabolic syndrome. 5 It has always been assumed that these beneficial effects are the result of the lipid-modifying effects of niacin.
However, recent data have indicated that niacin also decreases C-reactive protein levels, 6 improves endothelial dysfunction, 7, 8 increases the endothelial and leukocyte oxidation-reduction (redox) state in vitro, 9 inhibits cytokine-induced monocyte adhesion to human endothelial cells, 9, 10 improves plaque stability, and reduces thrombosis. 11 It also decreases cytokine-induced expression of vascular cell adhesion molecule 1 (VCAM-1), 9 intercellular adhesion molecule 1 (ICAM-1), 10 and monocyte chemotactic protein 1 (MCP-1) 9 in cultured human endothelial cells. These results suggest that niacin may prevent cardiovascular disease by inhibiting vascular inflammation via mechanisms independent of its lipid-modifying effects.
This question was addressed in the present study by determining if niacin inhibits acute vascular inflammation and improves endothelial function in normocholesterolemic and nonatherosclerotic rabbits, an animal model in which niacin does not affect plasma lipids. The results establish that niacin inhibits acute vascular inflammation and protects against endothelial dysfunction independent of changes in plasma lipid levels.
Methods
New Zealand white (NZW) rabbits (nϭ6 to 9 per group) were fed regular chow or chow supplemented with 0.6% or 1.2% (wt/wt) niacin for 14 days, before the insertion of a nonocclusive periarterial carotid collar. The animals were euthanized 24 hours after collar insertion, when the carotid arteries and thoracic aorta were extracted and subjected to immunohistochemical analysis for expression of VCAM-1, ICAM-1, MCP-1, intima-media neutrophil content (CD18ϩ cells), and myeloperoxidase (MPO) levels. Ex vivo isometric tension experiments were performed to assess the effects of niacin on endothelial function in the collared and noncollared carotid arteries and the thoracic aortic rings. Thoracic aortic rings were also incubated in vitro in the presence or absence of niacin and hypochlorous acid (HOCl).
Results

Niacin Attenuates Vascular Adhesion Molecule and Chemokine Expression
Three groups of NZW rabbits (nϭ6 to 9 per group) were used for the study. Group 1 was fed regular chow (nϭ9). The other groups consumed chow supplemented with 0.6% (nϭ9) or 1.2% (nϭ6) niacin (wt/wt) for 2 weeks, 12,13 after which plasma niacin levels (meanϮSEM) were 38Ϯ17 mol/L for the animals that received 0.6% niacin and 44Ϯ20 mol/L for the animals that received 1.2% niacin.
There were no significant differences in plasma total cholesterol, HDL cholesterol, triglyceride, nonesterified fatty acid, and apolipoprotein A-I levels between the groups when measured before niacin treatment and when euthanized (Supplemental Table; all supplemental material available online at http://atvb.ahajournals.org).
The implantation of a periarterial carotid collar did not affect endothelial morphological features, as assessed by immunohistochemical staining for CD31 (Supplemental Figure I) . As previously reported, the collar increased the endothelial expression of VCAM-1, ICAM-1, and MCP-1 14 (Figure 1 ). At 24 hours after collar implantation, endothelial VCAM-1 expression had increased from 0.3Ϯ0.1 to 4.8Ϯ0.6 image units (PϽ0.001). ICAM-1 expression increased from 1.0Ϯ0.2 to 6.4Ϯ0.4 image units (PϽ0.001), and MCP-1 expression increased from 0.2Ϯ0.1 to 6.0Ϯ1.1 image units (PϽ0.001) ( Figure 1A and B) . VCAM-1, ICAM-1, and MCP-1 mRNA levels increased 2.8-, 10.1-, and 19.8-fold, respectively (PϽ0.05) ( Figure 1C ).
Relative to the collared animals that received regular chow, dietary supplementation with 0.6% and 1.2% niacin de- creased the endothelial expression of VCAM-1 by 55Ϯ10% and 52Ϯ16%, respectively; ICAM-1 expression by 48Ϯ10% and 44Ϯ13%, respectively; and MCP-1 expression by 77Ϯ8% and 83Ϯ14%, respectively (PϽ0.05 for all) ( Figure  1A and B). Supplementation with 0.6% and 1.2% niacin also decreased VCAM-1 mRNA levels by 53Ϯ3% and 45Ϯ8%, respectively; ICAM-1 mRNA levels by 66Ϯ18% and 72Ϯ13%, respectively; and MCP-1 mRNA levels by 91Ϯ4% and 82Ϯ10%, respectively (PϽ0.05 for all) ( Figure 1C ).
Niacin Inhibits Neutrophil Infiltration and MPO Accumulation in the Intima-Media
The collar mediated intima-media neutrophil infiltration, with the area of CD18ϩ staining increasing from 1.0Ϯ0.1% in the noncollared arteries to 18.1Ϯ5.1% in the collared arteries (PϽ0.01) (Figure 2A and B) . Intima-media MPO levels were elevated in the collared arteries, as indicated by an increase in staining from 0.9Ϯ0.1% to 20.1Ϯ4.8% (PϽ0.01) (Figure 2A and B). This indicates that collar implantation could potentially lead to accumulation of neutrophil-derived reactive oxygen species (ROS). These collar-induced inflammatory responses were inhibited by niacin. Supplementation with 0.6% and 1.2% niacin inhibited neutrophil recruitment into the vessel wall by 86Ϯ7% and 89Ϯ5%, respectively (PϽ0.05); and reduced MPO levels by 73Ϯ7% and 81Ϯ6%, respectively (PϽ0.05) (Figure 2A and B). Across the collared arteries in all 3 groups of animals (nϭ18), neutrophil recruitment into the intima-media correlated positively with MPO accumulation (rϭ0.95, PϽ0.001) ( Figure 2C ), indicating that the neutrophils were activated and released MPO. Because the total blood neutrophil counts did not differ significantly between groups (Supplemental Figure II) , this result could not be attributed to niacin reducing the number of circulating neutrophils.
Niacin Increases Vascular Total Glutathione Content
It was previously reported that periarterial collars increase ROS production in the vessel wall. 14 Reduced glutathione (GSH) is the principal intracellular nonprotein thiol that scavenges ROS, 15 and niacin has been reported to increase the GSH content of cultured human aortic endothelial cells. 9 The results in Figure 3 establish that this is also the case in vivo. The total GSH content of the noncollared carotid arteries from the animals that received 0.6% and 1.2% niacin increased by 2.2Ϯ0.6-fold (PϽ0.05) and 2.9Ϯ0.7-fold (PϽ0.01), respectively, compared with control arteries (Figure 3A , open bars). In contrast, the total GSH content of the collared arteries from the control and the niacin-treated animals ( Figure 3A , closed bars) was decreased by 90% compared with the noncollared arteries. This is consistent with the GSH in these arteries being depleted by the ROS generated by the activated neutrophils.
There was also a 2.1Ϯ0.4-and a 2.3Ϯ0.5-fold increase in the total GSH content of the thoracic aorta from the animals that were supplemented with 0.6% and 1.2% niacin, respectively, compared with control (PϽ0.05) ( Figure 3B ). Ex vivo incubation with 1-mmol/L niacin increased the GSH content of control thoracic aortas by 2.9Ϯ0.5-fold (PϽ0.05). Incubation with 0.5-mmol/L niacin did not significantly increase the thoracic aorta GSH content ( Figure 3C ).
Niacin Inhibits Cytokine-Induced Inflammation in the Rabbit Thoracic Aorta
Niacin inhibits tumor necrosis factor ␣ (TNF-␣)-induced inflammation in cultured human endothelial cells. 9, 10 To determine if this is also the case in vivo, thoracic aortic segments from control rabbits were incubated for 6 hours with TNF-␣. This increased the VCAM-1 mRNA level by 2.9-fold, the ICAM-1 mRNA level by 1.8-fold, and the MCP-1 mRNA level by 3.4-fold compared with aortic segments incubated with phosphate-buffered saline (PϽ0.05) ( Figure 4A , open bars). When thoracic aortas from animals supplemented with 0.6% niacin were used in these incubations, VCAM-1, ICAM-1, and MCP-1 mRNA levels were decreased by 43.7Ϯ7.2%, 36.1Ϯ3.1%, and 48.2Ϯ10.6% ( Figure 4A , closed bars) compared with TNF-␣-stimulated aortic segments from the control animals (PϽ0.05).
The TNF-␣-induced inflammatory response was also reduced when thoracic aortas from control animals were preincubated in vitro with 1-mmol/L niacin. Relative to aortic segments stimulated with TNF-␣ and incubated without niacin, incubation with 1-mmol/L niacin decreased VCAM-1, ICAM-1, and MCP-1 mRNA levels by 57.6Ϯ8.9%, 38.9Ϯ6.1%, and 45.1Ϯ11.3%, respectively (PϽ0.05) ( Figure  4B ). Incubation with human endothelial cell growth medium serum-free culture medium alone did not change VCAM-1, ICAM-1, and MCP-1 mRNA levels in control thoracic aortic segments (Supplemental Figure III) .
Niacin Protects Against Collar-Induced Endothelial Dysfunction
ROS, such as HOCl, and cytokines, such as TNF-␣, which are produced by activated leukocytes under conditions of acute vascular inflammation, can induce endothelial dysfunction and decrease endothelial-derived nitric oxide bioavailability. 16 This decreases intracellular cyclic guanosine monophosphate (cGMP) production and reduces vasorelaxation in response to endothelial-derived nitric oxide agonists, such as acetylcholine. 16 The implantation of periarterial collars in rabbits is known to impair endothelium-dependent vasorelaxation. 17 This was confirmed in the present study, with acetylcholine-mediated endothelium-dependent vasorelaxation in carotid artery rings from collared rabbits being significantly reduced by 24-hour postcollar implantation ( Figure 5A , closed triangles) compared with rings from noncollared carotid arteries ( Figure 5A , open triangles) (PϽ0.001). Relative to what was observed for collared animals that did not receive niacin, collared carotid artery rings from rabbits that received 0.6% niacin ( Figure 5A , closed circles) displayed increased vascular relaxation (PϽ0.01) ( Figure 5A ).
The cGMP content in response to acetylcholine of collared arteries from animals that did not receive niacin was also decreased by 87.0Ϯ3.2% compared with that of noncollared arteries (PϽ0.001) ( Figure 5B) . Relative to what was observed for collared arteries from chow-fed animals, dietary supplementation with 0.6% niacin increased the cGMP content of the collared arteries by 2.9Ϯ0.5-fold (PϽ0.05) ( Figure  5B ). Collar implantation and treatment with niacin had no effect on sodium nitroprusside-induced endothelialindependent vasorelaxation ( Figure 5C ).
Niacin Protects Against HOCl-Induced Endothelial Dysfunction
The MPO that is generated by activated neutrophils consumes hydrogen peroxide, forming HOCl. 18 Because HOCl contributes to endothelial dysfunction directly by inhibiting nitric oxide production, 19 and because GSH is the principal scavenger of HOCl in endothelial cells, 20 we hypothesized that the increased aortic GSH content in the rabbits that received niacin may prevent HOCl-induced endothelial dysfunction.
When thoracic aortic rings from animals that did not receive niacin were preincubated with HOCl, acetylcholinemediated vasorelaxation was essentially abolished ( Figure  6A , open triangles). When, in contrast, aortic rings from animals that received 0.6% niacin were incubated with HOCl, relaxation was increased 6.1Ϯ1.4-fold at the highest concentration of acetylcholine (PϽ0.001) ( Figure 6A, open circles) . This is less than what was observed for the control ( Figure   Figure 3 . Niacin increases arterial total GSH content. Carotid collars were inserted into normocholesterolemic NZW rabbits (nϭ6 per group) fed regular chow (control [Ctrl]) or chow supplemented with 0.6% or 1.2% niacin (wt/wt), as described in the legend to Figure 1 . A, The total GSH content of the noncollared carotid arteries (open bars, nϭ6 to 9) and collared carotid arteries (closed bars, nϭ3 to 4) from animals that received regular chow (control) or dietary supplementation with 0.6% or 1.2% niacin. B, The total GSH content of thoracic aortic segments from animals that received regular chow (control, nϭ9) or chow supplemented with 0.6% (nϭ9) or 1.2% (nϭ6) niacin. C, The total GSH content of thoracic aortic segments from 3 control animals. The segments were incubated at 37°C for 24 hours with phosphate-buffered saline (control) or with niacin (final concentration, 0.5 or 1.0 mmol/L). Each experiment was performed in triplicate. Data are expressed as meanϮSEM (*PϽ0.05 compared with Ctrl).
6A, closed triangles) and the niacin-treated aortic rings ( Figure 6A , closed circles) that were incubated without HOCl.
The cGMP content in response to acetylcholine of aortic rings from chow-fed and niacin-supplemented animals was not affected by incubation with phosphate-buffered saline ( Figure 6B , closed bars). When aortic rings from the control animals were incubated with HOCl, cGMP production in response to acetylcholine stimulation was minimal ( Figure  6B , open bars), but increased by 4.1Ϯ0.9-fold for aortic rings from the animals that received dietary supplementation with 0.6% niacin (PϽ0.05) ( Figure 6B, open bars) .
A similar outcome was observed when thoracic aortic rings from animals that had not received niacin were incubated ex vivo with niacin. Compared with rings incubated with HOCl in the absence of niacin ( Figure 6C , open triangles), incubation with niacin afforded partial protection from the HOClinduced reduction in vasorelaxation in response to acetylcholine (PϽ0.001) ( Figure 6C , open circles). As was observed for thoracic aortic rings from niacin-treated animals, acetylcholine-stimulated relaxation of the rings incubated with HOCl and niacin was less than that of rings incubated without HOCl in the presence or absence of niacin ( Figure  6C, closed symbols) . The rings that were incubated with niacin in the absence of HOCl also had comparable cGMP contents in response to acetylcholine ( Figure 6D , closed bars). The cGMP level in response to acetylcholine in rings incubated with niacin plus HOCl, in contrast, was 3.3Ϯ1.0-fold (PϽ0.05) greater than that of rings incubated with HOCl in the absence of niacin ( Figure 6D , open bars).
Discussion
For the first time, to our knowledge, this report demonstrates that niacin markedly inhibits acute vascular inflammation and protects against endothelial dysfunction in normocholesterolemic and nonatherosclerotic rabbit arteries by processes independent of changes in plasma lipid and HDL levels. These beneficial effects of niacin were associated with an improved vascular redox state, which protected against ROSinduced endothelial dysfunction and inhibited cytokine-induced vascular inflammation.
A relationship between the anti-inflammatory properties of niacin and its ability to improve endothelial function has been demonstrated previously in human studies. For example, extended-release niacin decreased levels of C-reactive protein by 15% in patients with stable coronary artery disease. 6 It also decreased C-reactive protein levels and improved endothelial function in subjects with metabolic syndrome. 21 Improvement of endothelial function by extended-release niacin has also been reported in individuals with coronary artery disease. 7, 8, 22 However, the anti-inflammatory effects and improved endothelial function that were observed in those studies could not be dissociated from the increased HDL levels, which can also mediate these effects. 23 Evidence that niacin may have anti-inflammatory properties independent of its ability to increase HDL levels comes from a recent in vitro study 9 in which TNF-␣-induced VCAM-1 and MCP-1 expression and monocyte adhesion to cultured human aortic endothelial cells was significantly inhibited. Niacin also reduces ICAM-1 and platelet endothelial cell adhesion molecule 1 (PECAM-1) protein levels in TNF-␣-activated human umbilical vein endothelial cells. 10 The present results extend these findings by showing that these effects are also apparent in vivo and that they are independent of changes in plasma lipid levels.
Niacin is a precursor of nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, 24 and GSH, the principal intracellular nonprotein thiol responsible for maintaining intracellular redox states and protecting cells against oxidative stress. 15 Ganji et al 9 have shown that niacin increases nicotinamide adenine dinucleotide phosphate and GSH levels in vascular endothelial cells and decreases ROS formation and oxidative-related inflammatory responses. Consistent with these findings, we have shown that the total GSH content of aortic rings is increased by ex vivo incubation with niacin and by dietary niacin supplementation. These aortic rings were also protected against HOClinduced endothelial dysfunction and cytokine-induced vascular inflammation.
GSH is a well-recognized scavenger of MPO-derived oxidants, such as HOCl, 25 pathophysiological concentrations of which rapidly deplete intracellular GSH levels in cultured human umbilical vein endothelial cells. 20, 26 Consistent with this finding, the present results show that the total GSH content of collared arteries from control and niacin-treated animals was essentially depleted at 24 hours after collar implantation ( Figure 3A ). This suggests that the increased GSH may have reduced collar-induced ROS production, and raises the possibility that niacin, as a source of GSH, could potentially protect against ROS-induced injury. Together, these results indicate that niacin may protect against carotid collar-induced vascular inflammation and improve endothelial function, at least in part, 27 by increasing vascular GSH, which scavenges the ROS that is produced by neutrophilgenerated MPO in the vessel wall.
The precise mechanism of the anti-inflammatory effects of niacin is not entirely understood. Direct involvement of the niacin receptor G protein-coupled receptor (GPR)109A 28 is unlikely because it is not expressed in vascular tissues. 29 However, neutrophils are known to express a functional form of the GPR109A receptor that may be important for mediating nicotinic acid-induced neutrophil apoptosis. 30 This raises the possibility of indirect participation of GPR109A in the anti-inflammatory effects of niacin.
Activation of the transcription factor nuclear factor (NF) B by cytokines, such as TNF-␣, increases endothelial expression of VCAM-1, ICAM-1, and MCP-1; and is known to play an important role in the pathogenesis of atherosclerosis 31, 32 by recruiting circulating leukocytes into the vessel wall. 32, 33 Furthermore, NF-B is redox sensitive 34 and is activated by ROS, such as hydrogen peroxide, and ionizing radiation. 35 Depletion of cellular GSH can also degrade the NF-B inhibitory subunit. 36 When taken together, these observations suggest that the ability of niacin to inhibit acute vascular inflammation in the present study may be related to inhibition of NF-B activation. This is consistent with 2 recent reports 9, 10 showing that niacin reduces VCAM-1, ICAM-1, and MCP-1 expression in cultured endothelial cells by inhibiting NF-B. Although niacin has been used for more than 30 years to treat dyslipidemia in humans, the metabolic pathways it influences and the associated pharmacokinetics are not well established. In humans, niacin levels increase rapidly, peaking at approximately 1 hour after oral administration and returning to baseline by 2 hours after ingestion. 37, 38 As niacin was incorporated into chow to which the animals in the present study had unrestricted access, plasma niacin levels varied widely (Supplemental Figure IV) . This indicates that simply measuring plasma niacin levels does not accurately reflect the overall niacin concentrations achieved during the study period. Niacin is also metabolized to nicotinuric acid, which is cleared from the circulation at a much slower rate than niacin. 37 Further investigation is required to give an insight into the bioavailability of niacin in vivo and to investigate whether its metabolites also have cardioprotective properties.
In the present study, niacin treatment tended to decrease plasma triglyceride and nonesterified fatty acid levels (Supplemental Table) ; however, these reductions did not reach statistical significance (PϾ0.10 for all; nϭ6). This indicates that the markedly reduced vascular inflammation and improved endothelial function that was observed in the niacintreated animals cannot be attributed to changes in lipid profiles. Additional evidence that this is the case comes from the ex vivo study that showed that incubation with niacin protects against HOCl-induced endothelial dysfunction and cytokine-induced vascular inflammation in aortic rings from Figure 5 . Niacin protects against collar-induced endothelial dysfunction. Nonocclusive carotid collars were inserted into normocholesterolemic NZW rabbits (nϭ6 per group) that were fed regular chow or chow supplemented with 0.6% niacin, as described in the legend to Figure 1 . Relaxation of precontracted carotid artery rings in response to acetylcholine (ACh) (A) and sodium nitroprusside (SNP) (C) from noncollared (open triangles) and collared animals that received regular chow (closed triangles) and collared animals that received 0.6% niacin (closed circles) is shown. Experiments were performed in duplicate using arterial rings from 3 animals per group. The cGMP content of the carotid artery rings in response to acetylcholine is shown in B (nϭ6). Data are given as meanϮSEM (*PϽ0.05).
control animals that did not receive dietary supplementation with niacin ( Figure 6 ). Niacin can also change the composition of human HDL in ways that could potentially improve their anti-inflammatory properties. 39 The possibility that this may have occurred in the present study cannot be ruled out and warrants further investigation.
In conclusion, we have shown that niacin improves endothelial dysfunction and inhibits vascular inflammatory responses by increasing the vascular redox state and scavenging ROS without significantly affecting lipid levels. These findings indicate that niacin has multiple potential cardioprotective properties. They also offer a new insight into its mechanism of action in vivo. 
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